Uncertainty about what happens next can leave reporters doubting whether their contributions have any real effect. In this article, you’ll uncover what happens after an adverse drug reaction report is received, explaining each phase of the case reporting process so that every report becomes a catalyst for safety insight.

What initial checks and triage does an adverse drug reaction report undergo?

Drug safety plays a central role in handling any adverse drug reaction report. When processing an adverse drug reaction (ADR) report, the first steps typically involve initial checks and triage to ensure the report is complete, valid, and ready for further evaluation. Before anything else, the adverse drug reaction report must meet the minimum requirements to be considered a valid Individual Case Safety Report (ICSR) such as an identifiable patient, an identifiable reporter, a suspect drug and suspected adverse reaction. If key data are missing, the report will be flagged for follow-up.

Duplicate check is also performed on this stage. The report is then triaged based on seriousness and urgency. Serious ADRs (e.g., death, life-threatening, hospitalization) are prioritized. Unexpected or new signals may trigger expedited review. Reports involving special populations (e.g., children, elderly, pregnant women) may get special attention

How is the report validated and coded after an adverse drug reaction report is filed?

Once the adverse drug reaction report clears triage, it enters the critical phase of validation and coding. During validation, the case is examined for internal consistency (dates, sequence of events, cross-checks), completeness (mandatory fields present), and clarity of the narrative. If key data are missing or ambiguous, the report may be flagged for follow-up or held back until corrections are supplied.

Once the report is successfully validated, the clinical and narrative data are converted into standardized coding systems—commonly using MedDRA coding system for adverse event terms and the WHO Drug Dictionary (or equivalent) for medicinal products. This standardization promotes interoperability, ensures consistency across databases, and supports effective aggregate analysis, such as signal detection. Accurate coding is critical; errors in coding can weaken or mask important safety signals, potentially compromising pharmacovigilance efforts.

At Billev Pharma East, we integrate dedicated validation and medical-coding teams within our pharmacovigilance operations. From the moment a case is adjudged valid, we ensure rigorous quality controls, versioning, and audit-ready documentation so that each adverse drug reaction report is reliable and useable in further safety assessment.

When and how is follow-up information requested after an adverse drug reaction report is submitted?

After the adverse drug reaction report passes the validation stage, it’s common that some essential details remain missing or unclear. In such cases, a follow-up is initiated to request supplemental information. This step ensures completeness and strengthens the reliability of the data used for causality assessment and regulatory decision-making.

The timing of follow-up depends on the seriousness and potential impact of the adverse event: for severe or unexpected reactions, follow-ups are launched more promptly and often via direct contact with the reporter (healthcare professional, patient, institution). For less urgent cases, structured questionnaires (or follow-up queries) may be sent to collect missing lab results, outcome data, comorbidities, concomitant medications, or further clinical narrative. EMA guidelines even define Specific Adverse Reaction Follow-Up Questionnaires (AR FUQs) for cases that warrant tailored follow-up on certain reaction types.

The follow-up process should strike a balance — asking for enough detail to assess causality and seriousness, but avoiding overburdening the reporter. Clear deadlines, reminders, and tracking of responses are critical for efficiency. Some pharmacovigilance systems integrate automated alerts or dashboards to flag overdue follow-ups and escalate when necessary.

In practice, upon receiving the additional data, the case is updated, re-validated, and recoded if necessary, and then allowed to proceed into the next phases of review and signal detection. This follow-up step can materially change the conclusions about causality, seriousness, or expectedness and is essential for transforming a minimal case into a robust, analyzable adverse drug reaction report.

Types of follow-up requests and their timing

When a submitted adverse drug reaction report lacks certain details, different types of follow-up requests may be issued depending on urgency, case seriousness, or regulatory needs. The table below summarizes the main categories of follow-up requests:

How do regulatory authorities review and assess a submitted adverse drug reaction report?

After a submission of a adverse drug reaction report, it arrives at the stage where regulatory and safety authorities perform a structured assessment. This is a critical part in the case processing workflow, because decisions made here affect whether further action is necessary, whether a signal should be raised, or whether risk minimization steps should be revised.

Here is how this review and assessment typically occur:

• Regulatory intake & routing: the case is accepted into a national competent authority or into a centralized system (e.g. EudraVigilance in the EU) for review.
• Case triage to scientific review: cases are prioritized based on seriousness, novelty, expectedness, and regulatory interest. Those flagged as serious or unexpected go to expert committees or pharmacovigilance assessment teams.
• Causality assessment: medical reviewers evaluate whether there is a plausible link between the drug and the reported event. They consider factors such as temporal association, dechallenge/rechallenge information, alternative explanations, and known pharmacology.
• Comparison with existing knowledge: the reaction is compared against the known safety profile of the drug (e.g. product information, previous reports). If the event is new or not adequately characterized, it is considered unexpected and may warrant additional scrutiny.
• Risk–benefit evaluation: authorities assess whether the new information materially alters the benefit–risk balance of the drug. If so, regulatory action may be proposed (label updates, warnings, restricted use, or further studies).
• Decision & action: based on the assessment, regulators may recommend changes to labeling, request post-authorization safety studies, issue safety communications, or initiate further investigation.

The review process must comply with Good Pharmacovigilance Practices (GVP), particularly Module VI (collection and management of ICSRs) and Module IX (signal management) in the EU context.

Regulatory assessment is not the final stop; it often triggers downstream processes (signal detection, cohort studies, periodic reporting) that further shape the safety governance of the medicine.

What criteria determine the seriousness, causality, or expectedness after an adverse drug reaction report is filed?

Once an adverse drug reaction report has been processed through intake, triage, validation, and any necessary follow-up, it faces crucial medical review. In this stage, three primary dimensions are evaluated:

• Seriousness: whether the event leads to death, life-threatening conditions, hospitalization or prolongation thereof, disability, congenital anomaly, or other medically important outcomes.
• Causality (or relatedness): assessing how likely it is that the drug actually caused the event, considering timing, alternative causes, dechallenge/rechallenge data, and consistency with pharmacology.
• Expectedness: whether the observed reaction is consistent with the known safety profile of the drug (i.e. documented in the label or reference safety information). If it differs in nature or severity, it may be considered “unexpected.”

Depending on how these criteria are met, the case may qualify for expedited reporting, signal evaluation, or further investigation.

Example: causality categories via WHO-UMC system

A commonly used framework for causality is the WHO-UMC system, which classifies a case into categories like “certain,” “probable,” “possible,” “unlikely,” “conditional/unclassified,” or “unassessable,” based on objective and clinical evidence and documentation quality.

• Certain: strong temporal relationship, lack of alternative causes, positive dechallenge/rechallenge, and well-recognized event.
• Probable / Likely: reasonable temporal relationship, unlikely alternative causes, dechallenge positive, rechallenge not required.
• Possible: temporal relationship is present but alternative explanations are plausible.
• Unlikely or Unassessable: poor temporal relationship, insufficient documentation or contradictory information.

These judgments help prioritize cases in pharmacovigilance systems and guide regulatory decisions, such as whether to raise a signal or adjust risk management strategies.

How are duplicate reports handled in the case processing workflow?

Before submission of the adverse drug reaction report, the safety database is scanned for potential duplicates—entries that refer to the same patient event more than once. Such duplicates can distort statistics, skew signal detection, and mislead analysis. The system flags suspected duplicates by comparing fields like demographics, date of event, implicated drug, and reaction description. Once confirmed, one record is designated as the “master case,” and others are linked but not separately analyzed in aggregated safety reviews. This duplicate-management process is mandated under GVP Module VI Addendum I to preserve data integrity and accurate pharmacovigilance outputs.

In what ways is the filed adverse drug reaction report used for signal detection or safety monitoring?

Once a adverse drug reaction report is validated and duplication check is performed, it becomes part of a larger dataset used for signal detection—the process of identifying potential new safety concerns. These reports feed into databases like EudraVigilance or global systems where data mining and algorithmic checks look for disproportionality or unexpected patterns. Signals that emerge are then assessed, prioritized, and investigated further to see whether regulatory action or risk mitigation steps are needed.

Read also:

• What is patient safety and why pharmacovigilance matters for regulatory compliance?

Sources: 1 – EMA. (2016). Guideline on good pharmacovigilance practices (GVP) – Module VI Addendum I: Duplicate management of suspected adverse reaction reports, 2 – EMA. (n.d.). Guideline on good pharmacovigilance practices (GVP) – Module IX: Signal management (Rev. 1), 3 – EMA. (n.d.). Detailed guide regarding the EudraVigilance data management activities, 4 – EMA. (n.d.). EudraVigilance system overview, 5 – EMA. (n.d.). Signal management, 6 – EMA. (n.d.). Process description for managing duplicates in the context of the medical literature monitoring (MLM) service, 7 – EMA. (n.d.). SCOPE Training – Signal Management Best Practice Guide.